Tablet or composition having n-acyl ethanolamine and cannabinoid

1. A composition comprising:

n-acyl ethanolamine;

at least one cannabinoid; and

at least one terpene, wherein the n-acyl ethanolamine is in the form of lyophilized, dry preassembled micelles, and the at least one cannabinoid is entrapped in the micelles.

2. The composition as recited in claim 1 , wherein the n-acyl ethanolamine is selected from the group consisting of olioylethanolamide, palmitoylethanolamide, and combinations thereof.

3. The composition as recited in claim 1 , wherein the n-acyl ethanolamine is palmitoylethanolamide.

4. The composition as recited in claim 1 , wherein the at least one cannabinoid includes cannabigerolic acid.

5. The composition as recited in claim 1 , wherein the at least one terpene is selected from the group consisting of myrcene, limonene, caryophyllene, linalool, pinene, and combinations thereof.

6. The composition as recited in claim 1 , wherein the n-acyl ethanolamine is palmitoylethanolamide, the at least one cannabinoid includes cannabigerolic acid, and the at least one terpene includes myrcene.

7. The composition as recited in claim 1 , including by weight, 1 to 2000 parts of the n-acyl ethanolamine and 1 to 2000 parts of the at least one cannabinoid.

8. The composition as recited in claim 1 , including by weight, 10 to 1800 parts of the n-acyl ethanolamine and 1 to 100 parts of the at least one cannabinoid.

9. A tablet comprising:

one or more excipients;

n-acyl ethanolamine;

at least one cannabinoid; and

at least one terpene, wherein the n-acyl ethanolamine is in the form of lyophilized, dry preassembled micelles, and the at least one cannabinoid is entrapped in the micelles.

10. The tablet as recited in claim 9 , wherein the n-acyl ethanolamine is selected from the group consisting of olioylethanolamide, palmitoylethanolamide, and combinations thereof.

11. The tablet as recited in claim 9 , wherein the at least one cannabinoid includes cannabigerolic acid.

12. The tablet as recited in claim 9 , wherein the at least one terpene is selected from the group consisting of myrcene, limonene, caryophyllene, linalool, pinene, and combinations thereof.

13. The tablet as recited in claim 9 , wherein the n-acyl ethanolamine is palmitoylethanolamide, the at least one cannabinoid includes cannabigerolic acid, and the at least one terpene includes myrcene.

14. The tablet as recited in claim 9 , including by weight, 10 to 1800 parts of the n-acyl ethanolamine and 1 to 100 parts of the at least one cannabinoid.

15. A sublingual tablet comprising:

a compressed powder containing one or more excipients, n-acyl ethanolamine, at least one cannabinoid, at least one terpene, wherein the n-acyl ethanolamine is in the form of lvophilized. drv preassembled micelles, and the at least one cannabinoid is entrapped in the micelles.

16. The sublingual tablet as recited in claim 15 , wherein the n-acyl-ethanolamine is selected from the group consisting of olioylethanolamide, palmitoylethanolamide, and combinations thereof.

17. The sublingual tablet as recited in claim 15 , wherein the n-acyl-ethanolamine is palmitoylethanolamide, the at least one cannabinoid includes cannabigerolic acid, and the at least one terpene includes myrcene.

18. The sublingual tablet as recited in claim 15 , wherein clinical activities associated with the administration of the sublingual tablet include: chronic and neuropathic pain, inflammation, including peripheral neuropathies such as diabetic neuropathy, chemotherapy induced peripheral neuropathy, carpal tunnel syndrome, phantom limb pain, sciatic pain, osteoarthritis, low back pain, musculo-skeletal pain, failed back surgery syndrome, fibromyalgia, dental pain, post-stroke neuropathic pain, pain from multiple sclerosis, chronic pelvic pain, intestinal inflammation, migraine, cerebral ischemia, complex regional pain syndrome, postherpetic neuralgia, chronic pain from Lyme's Disease, ALS, urinary pain, and vaginal pain.